|
|
S*Bio Signs $550 Million Deal with Onyx
publication date: Jan 8, 2009
S*BIO of Singapore has optioned its two leading drug candidates to Onyx Pharmaceuticals in a deal that could be worth up to $550 million. As an upfront payment, S*Bio will receive $25 million in a combination of cash and equity investment. The agreement gives Onyx the right to exercise its options for S*BIO’s JAK2 inhibitors, SB1518 and SB1578, at certain predetermined development points. Each drug will be optioned separately. At that point, Onyx will have an exclusive license for all indications for the specific drug in the US, Canada and Europe. More details... Stock Symbols: (NSDQ: ONXX) (NYSE: NVS)
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|